Kuehn Law Investigates Kymera Therapeutics Officers and Directors

Kuehn Law, PLLC, a law firm specializing in shareholder litigation, announced on September 30, 2026, that it is investigating potential breaches of fiduciary duty by officers and directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR).

The investigation will examine allegations of self-dealing by corporate insiders. The firm stated that shareholders who have suffered losses due to these actions may be entitled to damages and may be able to effect corporate governance reforms.

Kymera Therapeutics is a biotechnology company focused on developing novel small molecule drugs that activate protein degradation. The company's stock performance and the progress of its drug candidates are key concerns for its investors.

Kuehn Law is requesting that long-term shareholders of KYMR contact the firm. The firm emphasized that consultations are free and without obligation, and it bears all case costs. Shareholders are advised to act promptly due to potential time limitations for asserting their rights.